Summary of Key Points Core Viewpoint - On December 29, several A-share listed companies disclosed their shareholding changes, with notable increases in holdings from companies like Kweichow Moutai and XCMG, while others like Leidian Weili and Oulutong announced reductions in their shareholdings [1]. Group 1: Shareholding Increases - Kweichow Moutai Group has cumulatively increased its shareholding by 3 billion yuan, and this buyback plan has been fully implemented [2]. - XCMG's controlling shareholder plans to increase its stake by no less than 80 million yuan and no more than 160 million yuan [2]. - Meihua Biological intends to repurchase shares worth between 35 million yuan and 50 million yuan [2]. - Xinghui Huan Materials plans to repurchase shares valued between 50 million yuan and 100 million yuan [2]. Group 2: Shareholding Reductions - Leidian Weili's shareholder Deng Hongzhong plans to reduce his stake by no more than 0.0427% [2]. - Oulutong's controlling shareholder Gan Yueke intends to reduce his stake by no more than 1.91% [2]. - Zhiyuan New Energy's shareholder Zhongzhihuiyuan plans to reduce his stake by no more than 1.53% [2]. - Baitong Energy's senior management Liu Muliang plans to reduce his stake by no more than 0.07% [2]. - Zhaoyan Pharmaceutical's actual controller Zhou Zhiwen plans to reduce his stake by no more than 1.99873% [2].

Summary of Key Points Core Viewpoint - On December 29, several A-share listed companies disclosed their shareholding changes, with notable increases in holdings from companies like Kweichow Moutai and XCMG Machinery, while others like Leidian Weili and Oulutong announced reductions in their shareholdings [1][2][3]. Group 1: Shareholding Increases - Kweichow Moutai's parent company has cumulatively increased its shareholding by 3 billion yuan, completing its buyback plan [2][3]. - XCMG Machinery's controlling shareholder plans to increase its stake by no less than 80 million yuan and no more than 160 million yuan [2][3]. - Meihua Biological intends to repurchase shares worth between 35 million and 50 million yuan [2][3]. - Xinghui Huan Materials plans to repurchase shares valued between 50 million and 100 million yuan [2][3]. Group 2: Shareholding Reductions - Leidian Weili's shareholder Deng Hongzhong plans to reduce his stake by no more than 0.0427% [2][3]. - Oulutong's controlling shareholder Wang Yueke plans to reduce his stake by no more than 1.91% [2][3]. - Zhiyuan New Energy's shareholder Zhongzhi Huiyuan intends to reduce his stake by no more than 1.53% [2][3]. - Baitong Energy's senior executive Liu Muliang plans to reduce his stake by no more than 0.07% [2][3]. - Zhaoyan Pharmaceutical's actual controller Zhou Zhiwen plans to reduce his stake by no more than 1.99873% [2][3].

昭衍新药（603127）(603127.SH)公告，公司实际控制人之一周志文拟自减持计划公告之日起15个交易 日后的3个月内通过集中竞价或大宗交易的方式减持不超过1498万股，不超过其持有股份的20.0466%， 不超过公司总股本的1.99873%。 ...

智通财经APP讯，昭衍新药(603127.SH)公告，公司实际控制人之一周志文拟自减持计划公告之日起15 个交易日后的3个月内通过集中竞价或大宗交易的方式减持不超过1498万股，不超过其持有股份的 20.0466%，不超过公司总股本的1.99873%。 ...

昭衍新药源(06127)发布公告，截至本公告披露日，北京昭衍新药研究中心股份有限公司(以下简称"公 司")实际控制人之一周志文持有公司股票74,725,981股，占公司总股本 9.9704%，其持有的股份来源于 首发前限售股份及公司资本公积金转增股份等。周志文拟自本减持计划公告之日起15个交易日后的3个 月内通过上海证券交易所以集中竞价或大宗交易的方式减持不超过1498万股,不超过其持有股份的 20.0466%，不超过公司总股本的1.99873%。 ...

昭衍新药（603127）源(06127)发布公告，截至本公告披露日，北京昭衍新药研究中心股份有限公司(以 下简称"公司")实际控制人之一周志文持有公司股票74,725,981股，占公司总股本9.9704%，其持有的股 份来源于首发前限售股份及公司资本公积金转增股份等。周志文拟自本减持计划公告之日起15个交易日 后的3个月内通过上海证券交易所以集中竞价或大宗交易的方式减持不超过1498万股,不超过其持有股份 的20.0466%，不超过公司总股本的1.99873%。 ...

JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 馮宇霞 董事長 中 國 北 京，2025年12月29日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫 雲 霞 女 士、羅 樨 女 士 及 顧 靜 良 先 生，獨 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603127 证券简称：昭衍新药 公告编号：2025-057 北京昭衍新药研究中心股份有限公司 关于股东减持股份计划公告 重要内容提示： 股东持股的基本情况 截至本公告披露日，北京昭衍新药研究中心股份有限公司（以下简称"公司"） 实际控制人之一周志文持有公司股票 74,725,981 股，占公司总股本 9.9704%，其 持有的股份来源于首发前限售股份及公司资本公积金转增股份等。 减持计划的主要内容 周志文拟自本减持计划公告之日起 15 个交易日后的 3 个月内通过上海证券 交易所以集中竞价或大宗交易的方式减持不超过 14,980,000 股,不超过其持有股 份的 20.0466%，不超过公司总股本的 1.99873%。减持计划实施期间，公司若发 生送红股、转增股本、增发新股或配股等股本除权事项的，减持数量将进行相应 调整。减持价格依据市场价格确定。 | 股东名称 | 周志文 | | | | --- | --- | --- | --- | | 股东身份 | 控 ...

昭衍新药公告，控股股东及实控人周志文持有7472.6万股，占总股本9.9704%。其拟自公告日起15个交 易日后的3个月内，通过上海证券交易所集中竞价或大宗交易方式减持不超过1498万股，不超过其持股 20.0466%，不超过公司总股本1.99873%。减持期间预计为2026年1月22日至2026年4月21日，股份来源 为IPO前股份及资本公积金转增股份，减持原因为自身资金需求。 ...

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) increased by 5.17%, currently trading at HKD 22.38, with a transaction volume of HKD 121 million, indicating a recovery in demand for preclinical CRO clients and a tight supply of experimental monkeys [5]. Group 1: Market Dynamics - There is a resurgence in demand for preclinical CRO services, particularly for new technology platforms such as large molecules (monoclonal antibodies, ADCs), small nucleic acids, peptides, and cell gene therapies, which require the use of macaques for safety evaluation tests [5]. - The price of 3-5 year old macaques has risen to HKD 140,000 each, reflecting a supply-demand imbalance in the market, which further supports the recovery of domestic innovative drug research and development [5]. Group 2: Financial Implications - According to estimates from Founder Securities, if Zhaoyan New Drug accounts for an average fair value of HKD 84,900 per monkey in 2024, and the price increases to HKD 140,000 by Q4 2025, the estimated new fair value addition for 2025 could be approximately HKD 220 million, based on a known population of 23,200 monkeys and an output rate of 17% [5].